Dayi Therapeutics, Inc.
Publicly observedNew York, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New York | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Dayi Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | EGQ3LAQJS311 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 May 2023Publicly observed
NIH SBIR/STTR award: Developing RNA therapeutics for rare neurodevelopmental disorders
USD 845,187.00 · Eunice Kennedy Shriver National Institute of Child Health and Human Development · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2023Publicly observed
NIH SBIR/STTR award: Developing RNA therapeutics for rare neurodevelopmental disorders
USD 853,987.00 · Eunice Kennedy Shriver National Institute of Child Health and Human Development · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.